Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for Hidradenitis Suppurativa
NCT03275870Phase 2Completed
- Start
- Sep 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in hidradenitis suppurativa (HS). Primary endpoint: Change in Disease Severity at 6 months. Started Sep 2017; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03275870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275870.